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Abstract
Background: Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group recommended that
patients with CKD should be assigned to stages and composite relative risk groups according to GFR (G) and
proteinuria (A) criteria. Asians have among the highest rates of ESRD in the world, but establishing the prevalence
and prognosis CKD is a problem for Asian populations since there is no consensus on the best GFR estimating
(eGFR) equation. We studied the effects of the choice of new Asian and Caucasian eGFR equations on CKD
prevalence, stage distribution, and risk categorization using the new KDIGO classification.
Methods: The prevalence of CKD and composite relative risk groups defined by eGFR from with Chronic Kidney
Disease-Epidemiology Collaboration (CKD-EPI); standard (S) or Chinese(C) MDRD; Japanese CKD-EPI (J-EPI), Thai GFR
(T-GFR) equations were compared in a Thai cohort (n = 5526)
Results: There was a 7 fold difference in CKD3-5 prevalence between J-EPI and the other Asian eGFR formulae.
CKD3-5 prevalence with S-MDRD and CKD-EPI were 2 - 3 folds higher than T-GFR or C-MDRD. The concordance
with CKD-EPI to diagnose CKD3-5 was over 90% for T-GFR or C-MDRD, but they only assigned the same CKD stage
in 50% of the time. The choice of equation also caused large variations in each composite risk groups especially
those with mildly increased risks. Different equations can lead to a reversal of male: female ratios. The variability of
different equations is most apparent in older subjects. Stage G3aA1 increased with age and accounted for a large
proportion of the differences in CKD3-5 between CKD-EPI, S-MDRD and C-MDRD.
Conclusions: CKD prevalence, sex ratios, and KDIGO composite risk groupings varied widely depending on the
equation used. More studies are needed to define the best equation for Asian populations.
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Background
Chronic kidney disease (CKD) increases the risks of car-
diovascular disease and ESRD progressively according to
the severity of CKD [1]. In 2002, the Kidney Disease
Outcomes Quality Initiative (KDOQI) organization pub-
lished a guideline for diagnosis and classification of
CKD into five stages according to severity using
glomerular filtration rate (GFR) as the main criteria [2].
The presence of proteinuria was mandatory for stages 1
and 2 (GFR > 60 ml/min/1.73 m
2). Patients with stage 3
(GFR 30 to < 60) or higher were regarded classified as
CKD without requirement for the presence of protei-
nuria. Recent studies have shown that individuals with
GFR 45 ml/min/1.73 m
2 or less had increased risks
compared to those with higher GFR [1,3-5]. The pre-
sence of proteinuria also increased cardio-renal events
significantly [1]. Therefore, in 2009, KDIGO (Kidney
Disease: Improving Global Outcomes) group
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according to proteinuria stages as well as by GFR stages
[1]. The diagnostic criteria for CKD remained
unchanged, but stage 3 should be divided into 2 sub-
stages: 3a (GFR 45 to < 60), and 3b (GFR 30to < 45). In
addition, clinicians and researchers were advised to use
a ‘heat map’ generated by composite rankings of relative
risks to categorize patients.
The numbers of patients in Asia including those in
Thailand with ESRD has been rising steadily over the
last decade [6,7]. Correct identification and staging of
CKD is essential to target care to patients with highest
risks and for planning of future healthcare policies. The
pooled analyses used to develop the new KDIGO guide-
lines employed the standard MDRD (S-MDRD) equation
to estimate GFR [3-5]. The S-MDRD equation was
designed from US white and black patients with CKD
[8]. It is well recognized that equations developed in
one CKD population may be inaccurate when applied to
another ethnic population or to those without known
CKD. Currently, there is no universal equation for Asian
subjects. MDRD based-equations have been developed
in Japanese and Chinese populations [9,10], but they
produced correction coefficients in opposite directions
to one another. S-MDRD may lead to overestimate of
GFR especially among those with higher GFR [11].
C h r o n i cK i d n e yD i s e a s e - E p i demiology Collaboration
(CKD-EPI) equation, was developed from subjects with
and without kidney diseases, and therefore, may be pre-
ferred for studying GFR in a largely normal population
sample [12]. More recently, a Japanese version for CKD-
EPI (J-EPI) was shown to be more accurate compared to
the Japanese MDRD equation in the Japanese popula-
tion [13]. Finally, a Thai GFR equation has also been
developed in a Thai CKD population [14].
It is the aim of KDIGO to establish global guidelines
for CKD [1]. However, at present, it is unclear which
equation(s) should be used in Asian populations to clas-
sify CKD. In addition, there is still limited data on the
prevalence of CKD class 3 subdivisions, and the num-
bers in different risk categories in Asian populations.
The prevalence of the subdivisions and each risk cate-
gory will depend on the equation used to estimate GFR.
In this study, we investigated the impact of different
GFR equations developed in Caucasian and other Asian
populations on GFR, and the prevalence of CKD in a
Thai cohort using the new KDIGO guidelines.
Methods
Study participants
During 1997-1998, 6152 employees of the Electricity
Generating Authority of Thailand (EGAT) were invited
to participate in a health survey [15,16]. All participants
completed a self-administered questionnaire and under-
went a physical examination. Blood samples were drawn
after 12 hours overnight fast. The study was approved
by the ethical committees of EGAT and Ramathibodi
Hospital. Written informed consent was obtained.
Laboratory measurements
Serum creatinine (sCr) was measured using a IDMS-
standardized enzymatic assay on the Vitros 350 analyzer
(Ortho-Clinical Diagnostics, USA), which has been
shown to produce similar results to the Roche assay
used in the MDRD study [17-19]. Details of the calibra-
tion procedure have been published [20]. Calibration
was performed using two levels (low; 0.753 mg/dL ±
0.021 and high; 3.916 mg/dL ± 0.083) of IDMS-Standard
Reference Material (SRM) 967. Mean concentrations
(coefficients of variation) for the two levels of SRM 967
were 0.749 mg/dL (1.64%), and 3.898 mg/dL (0.41%),
respectively. Stable quality control was maintained
throughout using the manufacturer’sq u a l i t yc o n t r o l
materials. Urine protein was detected by urinalysis
reagent strip (Bayer, Indiana, USA).
Estimated GFR (eGFR) Equations
SCr (mg/dl) was used to determine eGFR (ml/min/1.73
m
2) according to different formulae:
a) Chronic Kidney Disease-Epidemiology Collabora-
tion (CKD-EPI) = 141 × min(sCr/,1 ) a ×m a x ( s C r / ,
1)-1.209 × 0.993Age × 1.018 [if female] [12]
where  is 0.7 for females and 0.9 for males, a is
-0.329 for females and -0.411 for males, min indicates
the minimum of sCr/ or 1, and max indicates the max-
imum of sCr/ or 1.
b) Standard MDRD (S-MDRD) = 175 × sCr
-1.154 ×
Age
-0.203 × 0.742 [if female] [17]
c) Chinese MDRD (C-MDRD) = 175 × sCr
-1.154 ×
Age
- 0.203 × 1.233 × 0.742 [if female] [9,21]
d) Japanese CKD-EPI (J-EPI) = 0.813 × CKD-EPI [13]
e) Thai GFR (T-GFR) = 375.5 × sCr
0.848 ×A g e
-0.364 ×
0.712 [ if female] [14]
CKD staging
Subjects were divided into 5 stages by eGFR (G1-5) and
3 stages of albuminuria (A1-3) according to the 2009
KDIGO guidelines [1]. Because we did not have albumi-
nuria data, dipstick protein was used instead as follows:
A1proteinuria dipstick negative or trace, A2 1or 2+, A3
protein 3+ or more. CKD prevalence was assessed using
different equations. CKDALL represents CKD stages 1 to
5. CKD 3-5 represents eGFR < 60 ml/min/1.73 m2
regardless of proteinuria data. One of the concerns was
the high numbers of patients with CKD 3-5 in the older
age groups, in particular, those patients with stage 3a
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uated the prevalence of G3A1 in different age groups.
Concordance
CKD3-5 status concordance was assessed in pairs
between the three Asian equations versus CKD-EPI or
S-MDRD, and also between T-GFR versus the other
Asian equations. Concordant subjects included subjects
who fulfilled the criteria for CKD3-5 by both tested
equations, and subjects who did not fulfill the criteria
for CKD3-5 by both equations. The CKD3-5 status con-
cordance was expressed as a percentage of all subjects.
CKDALL stage concordance was assessed in pairs
between the three Asian equations versus CKD-EPI or
S-MDRD, and also between T-GFR versus the other
Asian equations. Subjects with no CKD (stage G1A1 or
G2A1) by both tested equations were excluded from the
analysis. Concordant subjects were those who were
assigned the same CKD stage by both pairs of the test
equations. This was expressed as a percentage of those
with CKDALL by either one of the pair using the
KDIGO classification [1] in which stage 3a and stage 3b
were considered as separate stages or by the KDOQI [2]
classification in which stage 3 was considered as one
stage.
Composite ranking of relative risks
The composite rankings for relative risks by GFR and
proteinuria was calculated based on 2009 KDIGO
recommendations using different equations as follows:
Risk Category No CKD (group 1-8) stages G1A1, G2A1;
Mild (group 9-14) stages G1A2, G2A2, G3aA1; Moder-
ate (group 15-21) stages G1A3, G2A3, G3aA2, G3bA1;
Severe (group ≥ 22) stages G3aA3, G3bA2-3, all G4 and
G5[1].
Statistical analyses
Continuous data is reported as mean (95% confidence
intervals). Categorical data is presented as frequency
and percentages. Continuous variables are compared
using Student’s t test or Wilcoxon rank sum test as
appropriate. Categorical variable were compared using
chi square test. All tests were two tailed, and a p-value
less than 0.05 is considered statistically significant. All
statistical analyses were performed using SPSS software
(SPSS Version 18; SPSS Inc, Chicago, IL).
Results
Study participants
A total of 5966 volunteered to be screened. Of these,
5526 subjects had complete data for analysis (table 1).
Almost all subjects were Thais or Thai-Chinese. About
75% of subjects were males, 11.6% had diabetes and
9.9% had proteinuria. Men were older and more likely
to have higher BMI, blood pressure, DM, and
hypertension.
All patients
Glomerular Filtration rate
GFR obtained by different equations were different to
one another (p < 0.001). C-MDRD and T-GFR produced
higher mean GFR whereas J-EPI produced much lower
GFR estimates (table 2). S-MDRD and CKD-EPI pro-
duced intermediate values. The maximum difference in
mean GFR was over 30 ml/min/1.73 m
2 ranging from
89.7 for C-MDRD to 64.6 with J-EPI.
CKD prevalence
T h ep r e v a l e n c eo fC K D ALL between various equations
was different (p < 0.001) except for between TGF and
C-MDRD. The prevalence of CKDALL for J-EPI was 3
Table 1 Participant Characteristics
All
(n = 5526)
Males
(n = 4121)
Females
(n = 1405)
P
Age (years) 48.4
(48.2-48.6)
48.7
(48-5-48.9)
47.5
(47.1-47,8)
< .001
Weight (kg) 64.8
(64.5-65.1)
67.3
(67.0-67.6)
57.5
(57.0-58.0)
< .001
BMI (kg/m
2) 24.25
(24.16-24.34)
24.35
(24.25-24.45)
23.95
(23.76-24.15)
< .001
SBP (mm Hg) 130.0
(129.4-130.5)
133.2
(132.6-133.8)
120.6
(119.6-121.6)
< .001
DBP(mmHg) 79.2
(78.8-79.5)
81.1
(80.7-81.4)
73.7
(73.1-74.3)
< .001
S creatinine (mg/dl) 1.08
(1.07-1.09)
1.15
(1.14-1.17)
0.86
(0.85-0.87)
< .001
Proteinuria (%) 9.9% 10.3% 8.8% NS
DM (%) 11.6 12.5 9.0 < .001
Hypertensive (%) 36.3 41.1 22.3 < .001
BMI, Body mass index; SBP systolic blood pressure; DBP diastolic blood
pressure, DM diabetes mellitus
Table 2 GFR according to different equations (n = 5526)
Equation
(N)
All
(5526)
Males
(4121)
Females
(1405)
S-MDRD 72.6
(72.1-73.0)
71.7
(71.1-72.2)
75.2
(74.2-76.2)
CKD-EPI 79.4
(78.9-79.8)
77.9
(77.3-78.3)
84.0
(83.0-84.9)
J-EPI 64.6
(64.2-65.0)
63.4
(62.9-63.8)
68.3
(67.7-69.1)
C-MDRD 89.6
(89.1-90.2)
88.6
(87.9-89.2)
92.9
(91.7-94.1)
T-GFR 82.4
(83.3-82.9)
84.5
(84.0-85.0)
78.0
(77.2-78.8)
Data shown as mean (95% CI) in ml/min/1,73 m
2.
eGFR by using one equation was different from eGFR by
all other equations (p < 0.001) for all, males and females
CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration
S-MDRD, standard MDRD; C-MDRD, Chinese MDRD; J-EPI, Japanese CKD-EPI; T-
GFR, Thai GFR.
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T h ep r e v a l e n c eo fC K D ALL was intermediate for the 2
Caucasian equations. CKDALL with S-MDRD was nearly
two times higher than with T-GFR. The prevalence of
CKDALL with CKD-EPI was about 5% higher than with
T-GFR.
T h ep r e v a l e n c eo fC K D 3-5 between various equations
was different (p < 0.001) except for between TGF and
C-MDRD. J-EPI produced 7 folds higher estimates than
T-GFR and C-MDRD. The 2 Caucasian formulae pro-
duced intermediate results, but CKD3-5 was still 2 and 3
folds higher than T-GFR. The prevalence of CKD stages
G1 and G2 were higher for T-GFR and C-MDRD,
whereas stage G3 was much higher for J-EPI. Compared
to others, a marked increase in stage G4 was also found
for J-EPI. Differences in G3aA1 accounted for a large
portion of the differences between equations.
CKD 3-5 status concordance
The concordance (Figure 1) with CKD-EPI was over
90% for T-GFR and C-MDRD with both the Asian
equations under-diagnosing CKD 3-5 compared to CKD-
EPI. On the other hand, the concordance of CKD-EPI
with J-EPI was only 74.2% with J-EPI over-diagnosing
CKD3-5 compared to CKD-EPI. The concordance for all
Asian equations and S-MDRD were only moderate and
slightly over 80%. C-MDRD and T-GFR tends to under-
diagnose CKD3-5 whereas J-EPI tends to over-diagnose
CKD 3-5. The concordance between T-GFR and C-
MDRD was excellent, whereas it was extremely poor
with J-EPI.
CKD ALL stage concordance
T h es t a g ec o n c o r d a n c ew a sh i g h e rw i t ht h e2 0 0 2
KDOQI criteria than with the 2009 KDIGO criteria.
CKDALL stage concordance with CKD-EPI was only 50-
60% for T-GF and C-MDRD, but only 15-30% for J-EPI.
In contrast, stage concordance with S-MDRD was 45-
55% for J-EPI and only 26-39% for C-MDRD or T-GFR.
The stage concordance with T-GFR was very poor for J-
EPI, but over 70% for C-MDRD.
Composite ranking of relative risks
For all equations, the numbers of subjects in each risk
category decreased with increasing severity of risks (Fig-
ure 2). The absolute numbers decreased approximately
4-5 folds from mild to moderate and by the same pro-
portion from moderate to severe. The numbers varied
strikingly according the equation used, but followed the
same ranking pattern across severity groups. The abso-
lute difference between equations varied most in the
mild category which ranged from 32% in J-EPI to 10.9%
in T-GFR or C-MDRD and were 20.8% and 14.0% for S-
MDR and CKD-EPI respectively.
Gender
Mean GFR was higher in females than in males for all
equations except T-GFR (Table 2). The mean female
male difference ranged from - 6.5 ml/min/1.73 m
2 for
T-GFR to + 6.1 ml/min/1.73 m
2 for CKD-EPI. In both
males and females, C-MDRD produced the highest GFR
estimates whereas J-EPI produced the lowest GFR esti-
mates. Different equations h a dm a r k e de f f e c t so nt h e
prevalence of male to female ratios of CKD 3-5 (Figure
3) which ranged from 0.5 for T-GFR to 1.5 for CKD-
EPI.
Age
Subjects were divided into 3 age groups: I (Age 20-39),
n = 908 (15.2%); II (Age 40-59), n = 4184 (75.6%) and
III (Age ≥ 60), n = 434 (7.9%). eGFR decreased (data
Table 3 GFR and proteinuria stages, and CKD prevalence by different equations according to 2009 KDIGO
classification
G1 G2 G3a G3b G4 G5 CKD ALL CKD 3-5
CKD-EPI 27.5 60.4 9.2 2.3 0.6 0.1 19.7
a 12.1
a
25.5 1.8 0.2 54.8 5.1 0.5 7.6 1.5 0.1 1.7 0.5 0.1 0.5 0.1 0.0 0.0 0.0 0.0
S-MDRD 11.2 67.5 16.8 2.7 0.6 0.1 27.1
a 20.2
a
11.1 1.0 0.1 61.8 5.2 0.5 14.6 2.0 0.2 2.0 0.6 0.1 0.5 0.1 0.0 0.0 0.0 0.0
J-EPI 3.2 58.9 30.7 5.8 1.3 0.1 43.0
a 37.9
a
2.9 0.2 0.1 54.1 4.4 0.4 27.4 3.0 0.3 4.7 1.0 0.1 1.0 0.2 0.1 0.1 0.0 0.0
C-MDRD 45.6 48.9 4.0 1.3 0.2 0.05 14.2
b 5.5
b
41.7 3.5 0.4 44.1 4.4 0.4 3.1 0.8 0.1 1.0 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0
T-GFR 29.2 65.5 4.3 1.1 0.1 0.04 14.0 5.4
27.1 1.8 0.3 58.9 6.0 0.6 3.2 1.0 0.1 0.9 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0
Data shown as percentages of all subjects (n-5526) for each GFR stage (G1-5) and for each proteinuria subdivision
(represented as 3 subdivisions of each G stage from A1 to A2 to A3 from left to right). CKDALL CKD from stage 1 to 5, CKD3-5 CKD stages 3 to 5
a CKD prevalence different compared to all other equations (p < 0.001)
b CKD prevalence different to other equations (p < 0.001) except with T-GFR
CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; S-MDRD, standard MDRD; C-MDRD, Chinese MDRD; J-EPI, Japanese CKD-EPI; T-GFR, Thai GFR
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tions. The absolute numbers varied widely, although the
relative order was similar across all age groups. In Age
group I, the prevalence of CKD 3-5 varied by over 100
folds. In Age group III, there was a marked difference in
CKD prevalence ranging from 14.7 to 63.1% for C-
MDRD to J-EPI, respectively. The prevalence of CKD
for all age groups was intermediate for the S-MDRD or
Figure 1 CKD 3-5 status concordance. Concordant subjects include subjects with (+/+) or without (-/-) CKD by both pairs of test vs. other
equation. Data expressed as percentage of all subjects (n = 5526). Discordant subjects are represented by +/- or -/+. CKD-EPI. CKD-EPI, Chronic
Kidney Disease-Epidemiology Collaboration; S-MDRD, standard MDRD; C-MDRD, Chinese MDRD, J-EPI Japanese CKD-EPI, T-GFR Thai GFR.
Figure 2 Proportion of subjects according to KDIGO 2009 risk categories. Mild (group 9-14): stages 1A2, 2A2, 3aA1; Moderate (group 15-21)
stages 1A3, 2A3, 3aA2, 3bA1; Severe (group ≥ 22): stages 3aA3, 3bA2-3, All 4 and 5. Data expressed as percentages of all subjects (n = 5526).
CKD-EPI. CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; S-MDRD, standard MDRD; C-MDRD, Chinese MDRD, J-EPI Japanese CKD-
EPI, T-GFR Thai GFR.
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group was as high as 10 to 15% compared to T-GFR or
C-MDRD.
T h ep r e v a l e n c eo fb o t hG 3 a A 1a n dh i g h e rs t a g eC K D
3-5 (CKD 3aA2-5) increased with age for all equations.
The ratios of G3aA1 to CKD 3aA2-5varied with different
equations, and decreased with age. G3aA1 accounted for
nearly all the patients with CKD 3-5 in Age group I,
between 57 to 72% in Age group II, and between 35 to
57% in age group III. The prevalence of G3A1 and CKD
3aA2-5 was much higher for J-EPI for all age groups.
There were 2 to 5 fold variations in 3aA1 in the oldest
age group. The prevalence was as high as 20.7% with S-
MDRD equation and only 7-8% for C-MDRD or T-GFR.
In Age group III, much of the differences in CKD 3-5
between S-MDRD, CKD-EPI, T-GFR could be
accounted for by differences in G3A1 since the preva-
lence of CKD 3aA2-5 were similar.
Discussions
Correct estimation of GFR is essential to diagnose and
stage CKD, to assess individual risks, and to allowing
comparisons between different populations in epidemio-
logic studies. The KDIGO analyses included some
patients from China and Japan, but most of the data
available for analysis is of mainly Caucasian or US black
subjects with eGFR calculated using S-MDRD formula
[1]. This study found that GFR estimates, CKD preva-
lence, proportions with increased risks, and gender
ratios in this Asian cohort varied widely depending on
the equation used. To our knowledge this is the first
study to evaluate the use of J-EPI and T-GFR equations
on the prevalence of CKD, and the concordance of
these new Asian formulae on CKD staging using the
new KDIGO guidelines.
In this study, CKD 3-5 prevalence was as high as 37.9%
with J-EPI whereas the prevalence was only 5-6% with
T-GFR or C-MDRD, 20.2% with S-MDRD and 12.1%
with CKD-EPI. The importance of choice of eGFR equa-
tions on CKD prevalence have been shown previously in
studies from the US and Europe [8,11,22]. In these stu-
dies, changing from S-MDRD to CKD-EPI resulted in
lower CKD prevalence estimates. In US white and black
subjects, CKD-EPI has emerged as the preferred equa-
tion for population studies as it has been shown to be
more accurate in CKD stage classification than the
MDRD study equation [11,12]. At present, it remains
unclear which is the best formula for Asian subjects.
CKD-EPI has recently been shown not to provide con-
sistent prediction of true GFR when applied to Asian
subjects [23].
In diagnosing moderate CKD (eGFR < 60) in a general
population, the concordance of T-GFR or C-MDRD
with CKD-EPI was over 90% compared to only 80%
with S-MDRD. In assigning stage for all subjects with
CKD (from stages 1 to 5), the concordance of T-GFR or
C-MDTRD equations was only about 50-60% with
CKD-EPI, and less than 40% with S-MDRD. The con-
cordance between T-GFR and C-MDRD was high, but
both had very poor concordance with J-EPI. Therefore,
it appears that T-GFR, C-MDRD and CKD-EPI may
produce comparable results in identifying individuals
Figure 3 Male: female ratios for CKD 3-5 prevalence by different equations. (n = 5526). CKD-EPI, Chronic Kidney Disease-Epidemiology
Collaboration; S-MDRD, standard MDRD; C-MDRD, Chinese MDRD; J-EPI, Japanese CKD-EPI; T-GFR, Thai GFR.
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stages of CKD were assessed, may be different in half
the time.
Using the 2009 KDIGO guidelines to subdivide stage
3, we showed that the CKD ALL, stage concordance
b e t w e e nt h eA s i a na n dC a u c a s i a ne q u a t i o n sd e c r e a s e d
by about 5-9% when compared to the KDOQI classifica-
tion in which stage 3 was considered as one stage.
KDIGO also recommended the use of composite rank-
ings of relative risks according to GFR and proteinuria
stages to assess individuals. In our analysis, the choice
of equation affected the numbers at risk quite markedly
especially those with mildly increased risks. Taken
together this data suggests that the choice of eGFR
equation has very considerable impact in diagnosing
CKD, CKD staging, individual risk assessment.
This study demonstrated that changing eGFR equa-
tions could affect CKD gender ratios quite dramatically.
Similar to our study, the male to female CKD ratio
among US NHANES subjects increased slightly when
the GFR equation was changed from S-MDRD to CKD-
EPI [12]. However, the largest difference in our study
was found when T-GFR was used, since this led to a
reversal in the male to female ratio even when com-
pared to C-MDRD. This finding, however, is not consis-
tent with the slightly higher male to female ratios
among those receiving renal replacement therapy in
Thailand and will require further analysis.
We showed that both stage G3aA1 and higher stages
of CKD increased with age, but the absolute numbers
and relative proportions depend on the equations used.
Young and middle age subjects with stage 3aA1 have
been shown to be at increased risks of renal events, car-
diac deaths and all cause mortality [4,24]. Among older
patients, similar increases in risk for renal events were
found, but the effects on cardiovascular deaths were less
consistent. In the oldest age group, nearly all the differ-
ences CKD 3-5 prevalence between S-MDRD, CKD-EPI
and C-MDRD could be accounted for by differences in
stage 3aA1. Clearly the magnitude of attributed risks for
developing cardio-renal complications for this stage will
depend on the equation used to stage CKD.
Differences between the Asian equations may be due
to differences in GFR measurement methods, creatinine
calibration or true differences in the study populations
[25,26]. J-EPI is now the equation of choice in the Japa-
nese population [13]. Muscle mass is a major determi-
nant in the relationship between serum creatinine and
true GFR [25]. Muscle mass is lower in Japanese com-
pared to American subjects [26,27]. This is consistent
with a coefficient of < 1 for the Japanese equation, but
still cannot account for the very high prevalence of
CKD when this equation is applied to other Asian popu-
lations. Indeed, when applied to the Thai population as
in this study, the prevalence of CKD is far too high for
J-EPI equation to be accurate.
This study employed IDMS-standardized enzymatic
method to measure serum creatinine similar to S-MDRD,
CKD-EPI, T-GFR and J-EPI. On the other hand, C-MDRD
was derived from Jaffe method after calibration to the Cle-
veland clinic laboratory, which was used to develop the
MDRD equation [9]. By applying a correction factor to
adjust for standardized enzymatic creatinine and Cleve-
land clinic Jaffe creatinine, systematic differences between
the two methods can be minimized [21]. Nonetheless,
creatinine method differences could account for some dif-
ferences between C-MDRD and other equations [25].
Methods to measure the reference GFR may contri-
bute to the differences between equations [28,29]. Iotha-
lamate clearance, used in the S-MDRD study, has been
shown to overestimate GFR when compared to standard
inulin clearance [30,31] and this could contribute to the
lower Japanese correction coefficient. Plasma clearance
of
99mTc-DTPA was used as a reference GFR method in
C-MDRD and T-GFR [9,14]. DTPA could overestimate
GFR when compared to inulin clearance [31]. In addi-
tion, Chinese and Thai studies employed quite short
clearance protocols which could further contribute to
overestimation of GFR compared to inulin [28] The
similarities for the T-GFR and C-MDRD equations may
in part reflect their common use of DTPA as the refer-
ence method [9,14]. Slight differences in protocol may
contribute to the different coefficients. Both Chinese,
Japanese, and Thai studies included only CKD patients,
and hence it is uncertain how well these formulae to
can be applied to normal subjects.
The limitations of this study include the fact that pro-
teinuria was defined by dipstick. Although previous stu-
dies have shown that dipstick proteinuria provide
similar risk prediction as albumin excretion [1], the use
of albumin to creatinine ratio would have allowed the
inclusion of those with microalbuminuria, and lead to
more accurate staging and risk assessment for our sub-
jects. Secondly, this study was designed to collect cardi-
ovascular risk factors, and hence there is limited data on
subjects with known kidney diseases beyond the pre-
sence of diabetes and hypertension.
Asians have among the highest rates of ESRD in the
world [6,7]. The Thai Renal Replacement Registry data
showed the steep increase of renal replacement preva-
lence from 302.6 per million populations in 2006 to
496.9 in 2008. Nonetheless, accurate estimation of CKD
prevalence remains a problem for Asian populations.
T h ep r e v a l e n c eo fC K D 3-5 observed in our study using
S-MDRD was fairly high, but is comparable to the 15%
observed in other population surveys from younger sub-
jects in Thailand, in which S-MDRD was used to classify
CKD [20,32]. Such high rate of CKD is a concern. It is
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tion of the Caucasian equations to the Thai population
or a genuine increase in CKD in our population. It
remains unclear which equation should be used to clas-
sify CKD in Thai or other Asian subjects. Although T-
GFR was developed in Thai CKD subjects, T-GFR equa-
tion may not be the ideal equation in our population
since there may be a bias especially among those with
lower GFR. For example, the creatinine value consistent
with a GFR of 5 ml/min/1.73 m
2 in a 50 year old male
w o u l db e1 1m g / d la n d3 0m g / d lb yS - M D R Da n dT -
GFR studies [14]. Nonetheless, by reclassifying our
patients with the T-GFR or C-MDRD will lead to a
reduction of those with CKD 3-5 by 2 to 3 folds with the
impact greatest among the elderly group.
Conclusions
This study showed that there is remarkable degree of
variability in CKD prevalence and risk estimates when
current equations developed in Caucasians and Asians
were applied to the Thai population. The results of this
study indicate that there is a need to develop a universal
A s i a ne q u a t i o nu s i n gs t a n d a rdized creatinine, and valid
common GFR reference method. The staging of CKD
initiated by KDOQI, and subsequently refined in the
2009 KDIGO convention represents major advances in
the field, but how best to apply such a staging system
on a global basis will require further study. The use of
the term ‘disease’ to describe asymptomatic laboratory
condition may cause unnecessary concern in patients
and clinicians. Identification of those truly at high risks
would enable targeting of scarce resources to those with
the greatest need. This is especially important in coun-
tries with limited resources such as many places in Asia,
who may not have developed equations of their own.
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